Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients

Table 1 General characteristics of gastric cancer patients and healthy controls n (%)

Characteristics	GCn = 304	Healthy controlsn = 392	Pearson’sχ2value	P value
Age (yr)			2.548	0.110
< 60	125 (41.12)	138 (35.20)
≥ 60	179 (58.88)	254 (64.80)
Sex			0.115	0.735
Male	223 (73.36)	292 (74.49)
Female	81 (26.64)	100 (25.51)
Smoker			0.314	0.575
Yes	92 (30.26)	111 (28.32)
No	212 (69.74)	281 (71.68)
Hypertension			0.012	0.931
Yes	78 (25.66)	102 (26.02)
No	226 (74.34)	290 (73.98)
Diabetes			2.591	0.108
Yes	52 (17.11)	50 (12.76)
No	252 (82.89)	342 (87.24)

GC: Gastric cancer.

Table 2 Distribution and regression analysis of the fibroblast growth factor receptor 4 Gly388Arg genotype in gastric cancer patients and healthy controls n (%)

Gly388Arg	GCn = 304	Healthy controlsn = 392	OR (95%CI)	P value
Genotype
GG	118 (38.8)	132 (33.6)	1
AG	124 (40.8)	188 (48.0)	0.738 (0.527-1.033)	0.076
AA	62 (20.4)	72 (18.4)	0.963 (0.633-1.466)	0.862
AA + AG	186 (61.2)	260 (66.3)	0.800 (0.586-1.093)	0.161
Allele
G	360 (59.2)	452 (57.7)	1
A	248 (40.8)	332 (42.3)	0.938 (0.756-1.163)	0.559

FGFR4: Fibroblast growth factor receptor 4; GC: Gastric cancer.

Table 3 Association analysis of the fibroblast growth factor receptor 4 Gly388Arg polymorphism and clinicopathological parameters in gastric cancer patients

Variables	Totaln = 304	Gly/Glyn = 118	Gly/Arg + Arg/Argn = 186	Pearson’sχ2value	P value
Age (yr)				0.013	0.909
< 60	125	49	76
≤ 60	179	69	110
Sex				1.398	0.237
Male	223	91	132
Female	81	27	54
Tumor size				0.198	0.656
≤ 3 cm	58	24	34
> 3 cm	246	94	152
Differentiation				2.122	0.145
G1 + G2	100	33	67
G3 + G4	204	85	119
Invasion depth				0.000	0.995
T1 + T2	49	19	30
T3 + T4	255	99	156
N stage				0.640	0.200
N0	82	27	55
N1 + N2 + N3	222	91	131
M stage				1.089	0.297
M0	274	109	165
M1	30	9	21
Clinical stage				0.980	0.322
I + II	103	36	67
III + IV	201	82	119
HER2 status				0.391	0.532
Negative	180	63	117
Positive	45	18	27

FGFR4: Fibroblast growth factor receptor 4; GC: Gastric cancer; HER2: Human epidermal growth factor receptor 2.

Table 4 Influence of fibroblast growth factor receptor 4 Gly388Arg polymorphism on gastric cancer survival

	Totaln = 257	Gly/Glyn = 100	Gly/Arg + Arg/Argn = 157	Log rankχ2value	P value
Age (yr)
< 60	98	37	61	1.459	0.227
≥ 60	159	63	96	1.734	0.188
Sex
Male	188	79	109	0.041	0.839
Female	69	21	48	0.018	0.894
Tumor size
≤ 3 cm	55	24	31	5.449	0.020
> 3 cm	202	76	126	0.308	0.579
Differentiation
G1 + G2	94	33	61	12.798	0.000
G3 + G4	163	67	96	2.637	0.104
Invasion depth
T1 + T2	46	19	27	4.745	0.029
T3 + T4	211	81	130	0.037	0.848
N stage
N0	73	24	49	6.647	0.010
N1 + N2 + N3	184	76	108	0.024	0.876
M stage
M0	235	94	141	0.027	0.869
M1	22	6	16	0.139	0.710
Clinical stage
I + II	91	33	58	4.615	0.032
III + IV	166	67	99	0.048	0.827
Chemotherapy (5-fluorouracil and cisplatinum)
Yes	156	55	101	0.019	0.891
No	51	21	30	0.442	0.506
HER2 status
Negative	157	54	103	0.458	0.499
Positive	36	15	21	1.014	0.314

FGFR4: Fibroblast growth factor receptor 4; GC: Gastric cancer; HER2: Human epidermal growth factor receptor 2.

Table 5 Frequency of the codon 72 genotype

	Gly/Gly	Gly/Arg	Arg/Arg
This study (China)	132 (33.6)	188 (48.0)	72 (18.4)
Chen et al[27] (China)	133 (29.1)	229 (50.1)	95 (20.8)
Zhu et al[28] (China)	231 (33.4)	346 (50.0)	115 (16.6)
Ma et al[29] (China)	243 (33.2)	368 (50.3)	121 (16.5)
Yang et al[30] (China)	123 (32.0)	195 (50.6)	67 (17.4)
Ma et al[14] (Japan)	67 (37.4)	87 (48.6)	25 (14.0)
Morimoto et al[15] (Japan)	39 (38.2)	50 (49.0)	13 (12.7)
Ho et al[34] (Singapore)	30 (34.1)	38 (43.2)	20 (22.7)
Bange et al[10] (Italy)	55 (44.7)	60 (48.9)	8 (6.5)
Spinola et al[11] (Italy)	112 (50.9)	83 (37.7)	25 (11.4)
Ho et al[35] (United Kingdom)	150 (51.5)	117 (40.2)	24 (8.2)
Wang et al[36] (United States-European)	53 (54.6)	40 (41.2)	4 (4.1)
Wang et al[36] (United States-African)	76 (80.9)	18 (19.1)	0 (0.0)
FitzGerald et al[13] (United States-European)	631 (50.4)	496 (39.6)	124 (9.9)
FitzGerald et al[13] (United States-African)	60 (75.0)	18 (22.5)	2 (2.5)